Compositions for HCV treatment

Details Compositions for HCV treatment Compositions for HCV treatment

2011-03-01

2011-03-01

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S049000

Reexamination Certificate

active

07897565

ABSTRACT:
The present invention concerns a pharmaceutical combination comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporine, e.g., a compound of formula I and b) a co-agent. Co-agents include, but are not limited to, interferons, a conjugate of interferon, antiviral agents, helicase inhibitors, protease inhibitors, polymerase inhibitors and nucleoside analogs. The instant pharmaceutical combination may be used, e.g., in treating subjects having a flaviviridae infection, e.g., a Hepatitis C infection.

REFERENCES:
patent: 5965527 (1999-10-01), Barriere et al.
patent: 5994299 (1999-11-01), Jean-Christophe et al.
patent: 6524570 (2003-02-01), Glue et al.
patent: 2002/0013272 (2002-01-01), Cavanak et al.
patent: 2002/0102279 (2002-08-01), Chiba et al.
patent: 2003/0216303 (2003-11-01), Ambuhl et al.
patent: 0 484 281 (1992-05-01), None
patent: 0484281 (1992-05-01), None
patent: 99/62540 (1999-12-01), None
patent: WO9962540 (1999-12-01), None
patent: 02/32447 (2002-04-01), None
patent: WO0232447 (2002-04-01), None
patent: WO 2004/002422 (2004-01-01), None
patent: 2005/021028 (2005-03-01), None
patent: WO2005/021028 (2005-03-01), None
patent: WO2006/038088 (2006-04-01), None
patent: 2006/071619 (2006-07-01), None
Evers et al., “Synthesis of Non-immunosuppressive Cyclophilin-Binding . . . ”, Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 4415-4419, 2003.
Inque Kazuaki et al., “Combined interferon alpha2b and cyclosporin . . . ”, Journal of Gastroenterology, vol. 38, No. 6, pp. 567-572, Jun. 2003.
Watashi K et al., “Cyclosporin A Suppresses Replication . . . ”, Hepatology, Williams and Wilkins, Baltimore, MD, US, vol. 38, No. 5, pp. 1282-1288, Nov. 2003.
Watashi Koichi et al., “Current approaches for developing new anti-HCV agents and analyses of HCV . . . ”, Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US, vol. 55, No. 1, pp. 105-110, Jun. 2005.
U.S. Appl. No. 10/570,097, filed Dec. 7, 2007, Makoto Hijikata, K. et al.
U.S. Appl. No. 11/719,684, filed Jan. 29, 2009, Weidmann, B.
U.S. Appl. No. 12/444,941, filed Apr. 9, 2009, Kohjima M. et al.
U.S. Appl. No. 11/572,110, filed Jan. 11, 2008, Cornu-Artis, C., et al.
Inoue et al. “Hepatitis C, virus and cyclosporin A”, Igaku no Ayumi, 193(12), pp. 951-954 (2000) Included are the English abstract, the original doucment in Japanese, and an English translation of the original Japanese document.
Retrieved from: http://www3.niad.nih.gov/topics/hepatitisC/prevention.html, 2009, 2 pages [Retrieved on Jun. 27, 2009].
Inoue et al. “Antiviral effect of cyclosporin A”, Antiviral Development and Therapy Poster Presentation, National Institutes of Health, Jun. 6-9, 1999.
Steinkasserer et al. “Mode of action of SDZ NIUM 811, a nonimmunosupressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1); interference with early and late events in HIV-1 replication”, Journal of Virology, vol. 69, 814-824 (Feb. 1995).
Kozlowski et al., ,,Development of pegylated interferons for the treatment of chronic hepatitis C, BioDrugs, vol. 15, No. 7, pp. 419-429 (2001).
Hansson, 2004, Journal of Bioenergetics and Biomembranes, 36, 407-413.
Papageorgiou, 1996, Bioorganic and Medicinal Chemistry Letters, 6, 23-26.
Billich A et al. “Mode of Action SDZ NIM 811, a Nonimmunosuppressive Cyclosporin Å analog with Activity against Human Immunodeficiency Virus (HIV) Type 1: Interference with HIV Protein-Cyclophilin A Interactions”, Journal of Virology, vol. 69, No. 4, pp. 2451-2461 (1995).
Yoshiba et al. “Interferon and cyclosporin A in the treatment of fulminant viral hepatitis”, Journal of Gastroenterology, 30:67-73 (1995).
Renken, J., Observations under Article 115 EPC,Hoffmann Eitle, Jun. 22, 2007, pp. 2-7.
EPO, Third Party Observations Under Article 115 EPC, EP 04 764 762.3 (WO 2005/021028) Novartis, Feb. 19, 2007, pp. 1-4.
EPO, Observations by third party pursuant to Art. 115 EPC, Art. 54 EPC, Art. 56 EPC, ART 123(2) EPC, Art. 83 EPC, Art 84 EP, Feb. 8, 2007, pp. 1-6.
Watashi, Koichi et al. “Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents”, Biosis, Biosciences Information Service, Philadelphia, PA, US; vol. 55, No. 1, pp. 105-110, Jun. 2005.
Duncan and Youossi (2003), Cleveland Clinic, J. Med., 70:S21-S26.
Shiffman (2004), Cleveland Clinic, J. Med., 71:S13-S16.
Agid et al., “MR diffusion-weighted imaging in a case of West Nile virus encephalitis”, Dec. 23, 2003, Neurology. vol. 61., No. 12, pp. 1821-1823.
Ravindra, K. V. et al., “West Nile virus-associated encephalitis in recipients of renal and pancreas transplants . . . ”, May 1, 2004, Clinical Infectious Diseases, vol. 38, No. 9, pp. 1257-1260.
Quesniaux, V. F. J. et al, “Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive . . . ”, 1987, European Journal of Immunology, vol. 17, No. 9, pp. 1359-1365.
Papatheodoridis and Cholongitas (2003), J. Viral Hep., 11:287-296.
Tripi, et al., “Interferon-alpha Alone versus interferon-alpha plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Pervious Interferon-alpha treatment.”, BioDrugs, vol. 13, No. 4, pp. 229-304 (Apr. 2000).
Brown, et al., “Liver Transportation”, Current opinion gastroenterology, vol. 17, No. 3, pp. 299-303 (May 2001).
Ferenci, P., International Journal Of Clinical Practice, vol. 57, No. 7, pp. 610-615, “Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C”, Sep. 7, 2003.
Manns, M.P., et al., The Lancet, vol. 358, No. 9286, pp. 958-964, “Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial”, Aug. 2001.
Manzarbeitia, C., et al., “40 kDa Peginterferon alfa-2A (PEGASYSs®) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT); preliminary results of a randomized multicenter trial”, p. 406A, AbstractsAASLD No. 938, Hepatology, Oct. 2001.
Nakagawa, M., et al., Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, FL, vol. 313, No. 1, pp. 42-47, “Specific inhibition of hepatitis C virus replication by cyclosporin A”, Jan. 2, 2004.
International Search Report and written opinion for PCT/EP2005/007633, dated Oct. 19, 2005.
Bizollon T. et al., “Histological Benefit of Retreatment by Pegylated Interferon Alfa-2b and Ribavirin in Patients with Recurrent Hepatitis C Virus Infection Posttransplantation”, American Journal of Transplantation, vol. 7, pp. 448-453, (2007).
Cotler, Scott J. et al., “A Pilot Study of the Combination of Cyclosporin A and Interferon Alfacon-1 for the Treatment of Hepatitis C in Previous Nonresponder Patients”, J Clin Gastroenterol , vol. 36 (4), pp. 352-355, (2003).
Dasilva, et al. (2002) J. Gastroenterol 37:732-36F.
Heathcote, et al. (1998) Heptatology 27:4, pp. 1136-1143.
Package Insert for Intron A, Revision Jul. 2007.
Fukushima et al., “Fasudil hydrochloride hydrate, a rhokinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells”, 2005,Liver International, vol. 25, pp. 829-838.
Fukushima et al., “Hydroxyfasudil, a Rho-kinase (ROCK) inhibitor suppresses cell growth and collagen production in rat hepatic stellate cells”, 2003, Hepatology, vol. 38, No. 4, Suppl. 1, p. 562A.
Nakamuta et al. , “Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells”, 2005, Transplantation Proceedings, vol. 37, No. 10.
Inoue et al., “Combined interferon A2b and cyclosporine A in the treatment of chronic hepatitis C: controlled trial”, Journal of Gastroenterol, vol. 38, No. 6, pp. 567-572, , Jun. 2003.
Inoue. 2001,

Affiliated with

Also associated with

Rating

Compositions for HCV treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for HCV treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for HCV treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2760208